Reconsidering GLYNAC: What the Evidence Actually Says About Glycine, NAC, Reversing Aging, and Life Extension
The information in this article is not intended as, and should not be taken as, medical advice. Interventions like exercising, dietary changes, and taking medications and supplements can have both benefits and side effects, Please consult with a medical professional about any medical concerns. See full Medical Disclaimer
by Nils Osmar
In the summer of 2022, a small clinical trial from Baylor College of Medicine generated headlines suggesting that a simple combination of two amino acids — glycine and N-acetylcysteine, sold under names like GLYNAC — could reverse several hallmarks of aging in older adults. A wave of supplement launches, podcast appearances, and longevity-community enthusiasm followed.
Four years on, with additional animal data, a cognitive pilot, and one serious independent replication attempt on the books, it is worth asking a quieter question: what does the evidence actually support?
The short answer is that GLYNAC is more mechanistically interesting, and its human evidence base is promising, but is thinner than most popular coverage implies. Here is a careful re-read — what’s known, what’s uncertain, and what a reasonable person might do with that picture.
Your donations make this website possible. To donate using Buymeacoffee, please visit buymeacoffee.com/nilsosmar
What GLYNAC is
GLYNAC is a 1:1 combination of glycine and N-acetylcysteine (NAC). Both are amino acids: glycine a simple one the body makes on its own, NAC a stable, bioavailable form of cysteine. Taken together, they supply the two rate-limiting building blocks the body needs to synthesize glutathione, the most abundant intracellular antioxidant.
You cannot usefully take glutathione itself as a pill — it is broken down in the gut. (There is some evidence that liposomal glutathione does get into ourselves, but as always, confirming studies are needed. See “About Liposomal Glutathione” at the bottom of the article.)
What cells need is raw material, and what they reportedly run short of with age is glycine and cysteine. Rajagopal Sekhar, the Baylor endocrinologist who has led most of the GLYNAC research for two decades, calls the combination the “Power of 3,” shorthand for the three separate actors: glycine, cysteine, and the glutathione they help build. Each has biochemical effects in its own right, which is part of why the combination may do more than either amino acid alone.
Dose and proportion
The research dose is substantial. Sekhar’s trials use approximately 100 milligrams per kilogram of body weight per day of each amino acid. For a 70-kilogram adult, that works out to roughly 7 grams of glycine and 7 grams of NAC daily. Most commercial supplements sell 600 to 1,200 milligrams of each — closer to a starter dose than a research dose.
This mismatch matters. Claims drawn from clinical trials use high doses; products on shelves typically deliver a fraction. A person wanting to replicate the Sekhar protocol would need several grams of each per day, not a single capsule. A 2022 dose-finding trial from the Nestlé Institute of Health Sciences tested 2.4, 4.8, and 7.2 grams per day (split into two doses) and confirmed that all three doses produced prompt, measurable rises in plasma glycine and cysteine — so the amino acids do get absorbed. The question, as we will see, is whether higher blood levels reliably translate into the downstream effects that matter.
The evidence — and its limits
The strongest GLYNAC trial in humans is Kumar et al., published in The Journals of Gerontology in 2023. It was a 16-week, placebo-controlled randomized trial in 24 older adults (average age 71) randomized to GLYNAC or an isonitrogenous alanine placebo, with 12 young adults supplemented for two weeks as a reference group. After 16 weeks, the GLYNAC group showed increases in red-blood-cell and muscle glutathione, reductions of roughly 70 percent in some markers of oxidative stress, improvements in mitochondrial fatty-acid oxidation, faster gait speed, better grip strength, reduced waist circumference, and changes in multiple molecular markers associated with aging cell biology. The placebo arm showed no such changes.
These are impressive numbers, and the study is carefully executed. But it is 24 people, from one laboratory, in participants preselected for certain metabolic features (higher BMI, elevated triglycerides). The young-adult group was not placebo-controlled and received GLYNAC for only two weeks, so the trial should not be read as a direct demonstration that “old was made young.”
Then there is the independent replication attempt. Lizzo et al. from the Nestlé Institute ran a 114-participant randomized trial in healthy older adults — three GLYNAC doses against placebo, with total glutathione as the pre-specified primary endpoint. After two weeks, GLYNAC did not significantly raise total glutathione or the reduced-to-oxidized glutathione ratio at any dose. Only in a post-hoc subgroup — participants with both high baseline oxidative stress and low baseline glutathione — did the higher doses produce increases.
Two weeks is shorter than Sekhar’s 16 weeks, and that matters: glutathione rises progressively over months. But the Lizzo result still complicates the simple story. It suggests that in healthier older adults without significant existing deficiency, GLYNAC may do less than the flagship trial implied. The people most likely to benefit may be those who most resemble Sekhar’s recruits — older adults with metabolic stress and measurable glutathione deficiency — rather than generally healthy agers. This remains a hypothesis rather than a settled finding, but it is the most parsimonious reading of the two trials taken together.
Which aging markers actually responded
The 2023 Baylor trial reported changes in biomarkers tied to several of the widely cited “hallmarks of aging,” the framework originally articulated by López-Otín and colleagues. Specifically, Kumar et al. reported improvements in markers of mitochondrial dysfunction (mitochondrial biogenesis markers, fatty-acid oxidation), deregulated nutrient sensing (AMPK signaling, insulin resistance), altered intercellular communication (inflammation markers), loss of proteostasis, genomic instability (reduced 8-OHdG, a DNA-damage marker), cellular senescence (reduced p16INK4a), and stem-cell exhaustion (Pax7 expression).
This is a striking list. It is also a list of biomarkers, not of clinical outcomes. A reduction in a senescence marker is not the same as a demonstrated longer healthspan. The molecular signal is coherent and points in a plausible direction, and the functional improvements — gait speed, grip strength — are meaningful in their own right. But the leap from “biomarkers improved” to “aging was reversed” is a rhetorical one, not an empirical one, and careful readers should keep that distinction in view.
A sex-specific wrinkle
One of the more interesting recent findings concerns sex. In a 2025 study in aged mice, Tyrrell and colleagues found that GLYNAC supplementation for twelve weeks improved cardiac diastolic function, exercise performance, and mitochondrial enzyme activity in old male mice — but had less of an effect in old female mice. The proposed explanation is that females, even in old age, maintain higher baseline glutathione and lower oxidative damage, partly due to long-duration estrogen effects. There is simply less room for GLYNAC to improve things.
This is a mouse study, and human sex-specific effects have not been formally tested. Sekhar’s human trials have included both sexes, but they have been too small to detect sex differences if they exist. Women considering GLYNAC should know that the clearest preclinical cardiac benefits have so far been in males, and that the human question remains open.
Dose timing and duration
There is no published human trial comparing once-daily GLYNAC to divided doses. What most people do — and what both the Sekhar and Lizzo studies actually used — is to split the daily dose into two, typically morning and evening, taken with meals. The rationale is pharmacokinetic rather than outcome-based: oral NAC has relatively low bioavailability (roughly 4 to 10 percent) and a half-life of about six hours, so divided dosing keeps circulating levels steadier across the day. Taking GLYNAC with food also reduces the gastrointestinal discomfort that higher doses can otherwise cause.
Duration appears to matter more than within-day timing. An open-label pilot published in 2021 by the same Baylor group found that benefits accumulated over 24 weeks of supplementation and then declined over the subsequent 12 weeks once GLYNAC was stopped. Whatever GLYNAC offers, it appears to require ongoing use rather than a one-time course.
Taking Glycine Without NAC — Or Vice Versa
In the NIA Interventions Testing Program, glycine alone modestly extended lifespan in both male and female mice. NAC has never shown a comparably clean lifespan benefit — the best available mouse data suggest any apparent effect may have been confounded by reduced food intake — and chronic high-dose NAC, when taken without glycine, has been linked, in preclinical studies, to accelerated growth of pre-existing lung tumors. These findings reinforce the case for the combination rather than NAC taken alone.
The bottom line
GLYNAC is mechanistically coherent, apparently well tolerated at the doses studied, and has produced genuinely interesting signals in one well-done but small human trial and in multiple animal studies. It is also under-replicated, tested almost entirely in a single laboratory, and its benefits may depend heavily on who is taking it. An older adult with measurable oxidative stress, glutathione deficiency, and metabolic features like central obesity is the person most likely to resemble Sekhar’s responders. A lean and metabolically healthy 55-year-old may see relatively little.
When compared with other purported (and overhyped) anti-aging supplements, in particular ones such as resveratrol which have almost zero evidence to support them, but which some people are still spending money on, GLYNAC looks promising. But it would be an overstatement to say that it’s benefits have been proven.
Caveats
A few practical caveats. GLYNAC can interact with blood thinners and some cardiovascular medications, and should be paused before elective surgery. High-dose antioxidant regimens also carry a theoretical complication worth naming: some preclinical studies suggest that chronic NAC can accelerate the growth of existing lung tumors in mouse models. This is not a settled clinical risk for supplement users, but it is reason for caution in anyone with a cancer history or active disease, and a reason to keep expectations about open-ended long-term use modest. Larger, independent human trials are genuinely needed. Until then, GLYNAC is worth following — with appropriate humility about what we still do not know.
What About Liposomal Glutathione?
A key benefit of GLYNAC is the evident increase in glutathione. So it’s worth looking for a moment at how it compares to other ways of increasing this compound.
There is genuine, though modest, evidence that liposomal formulations of glutathione work. The best-cited human study is Sinha et al. 2018 (European Journal of Clinical Nutrition): a one-month pilot in 12 healthy adults using a liposomal formulation (Tri-Fortify) at 500 or 1,000 mg/day. After two weeks they saw 40% increases in whole-blood GSH, 25% in erythrocytes, 28% in plasma, and — most strikingly — 100% increases inside peripheral blood mononuclear cells (immune cells). Oxidative stress markers also fell: 35% reduction in plasma 8-isoprostane.
A separate six-month trial comparing 250 vs 1,000 mg/day liposomal GSH found 30–35% increases in red blood cell, plasma, and lymphocyte GSH at the higher dose. A 2024 trial and a 2026 one comparing different encapsulation technologies (micellar vs liposomal vs standard) confirmed the general pattern: encapsulation improves bioavailability, plain powder doesn’t.
Caveats about liposomal glutathione
- The Sinha study (the most-cited one) had no placebo control and was funded by the manufacturer that makes the product studied. That doesn’t invalidate it, but it’s worth flagging.
- Sample sizes are small — typically 12 to 20 participants.
- The very large numbers you’ll see in marketing copy (“100-fold!” “2,250% improvement!”) trace back to one preclinical animal-pharmacokinetics paper (Sinha et al. 2014), not to human clinical results. Human increases are more in the 25–100% range depending on compartment, which is still meaningful but much more modest.
- No studies directly compare liposomal glutathione against GLYNAC for the aging-hallmark-type outcomes that Sekhar has measured. So whether liposomal GSH reaches the cellular compartments that matter for mitochondrial function, insulin resistance, or the senescence markers is an open question. The Sinha study’s finding of 100% PBMC increases is suggestive but not definitive.
What I am doing
to me, the evidence that there are benefits to taking GLYNAC are convincing enough that I am currently taking it. I usually. take 7 g of NAC along with 7 g of glycine in the morning. I don’t split my dose, partly because I’m trying to separate it by at least an hour from other supplements , which is easier if I take it all at once. There are no studies looking at what happens if we take GLYNAC, for example, along with supplements, such as NMN or NR or astaxanthin, or other compounds that show a promise of possible anti-aging benefits. In the absence of studies, I’m trying to separate supplements by at least an hour or two from other compounds to the extent possible. I plan to have my blood tested soon and enter the results into PhenoAge calculator, something I do every month or two. After that, I’ll be taking a break from GLYNAC and taking liposomal glutathione for a while. I’ll share the results when I know them.
Should you take GLYNAC?
It would be nice if someone could provide a clear answer, wouldn’t it? But the truth is that no one knows. To me, speaking only for myself, there’s enough evidence of benefits that I plan to keep taking it, at least until my next blood test. You will have to decide for yourself. The usual caveat of consulting with a medical professional before taking compounds with possible anti-aging benefits, and checking to make sure there are no side effects in conjunction with other medications you may be taking, of course applies.
